{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:57:43Z","timestamp":1758272263195,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s10147-020-01712-y","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T14:04:46Z","timestamp":1591106686000},"page":"1695-1703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-912X","authenticated-orcid":false,"given":"Wataru","family":"Fukuokaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"1712_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"1712_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630\u2013642. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002","journal-title":"Eur Urol"},{"key":"1712_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.juro.2013.05.005","volume":"190","author":"MS Cookson","year":"2013","unstructured":"Cookson MS, Roth BJ, Dahm P et al (2013) Castration-resistant prostate cancer: AUA Guideline. J Urol 190:429\u2013438. https:\/\/doi.org\/10.1016\/j.juro.2013.05.005","journal-title":"J Urol"},{"key":"1712_CR4","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/annonc\/mdy406","volume":"29","author":"AJ Armstrong","year":"2018","unstructured":"Armstrong AJ, Lin P, Higano CS et al (2018) Development and validation of a prognostic model for overall survival in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer. Ann Oncol Off J Eur Soc Med Oncol 29:2200\u20132207. https:\/\/doi.org\/10.1093\/annonc\/mdy406","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1712_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mdv594","volume":"27","author":"KN Chi","year":"2016","unstructured":"Chi KN, Kheoh T, Ryan CJ et al (2016) A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol 27:454\u2013460. https:\/\/doi.org\/10.1093\/annonc\/mdv594","journal-title":"Ann Oncol"},{"key":"1712_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clgc.2019.04.010","volume":"17","author":"W Fukuokaya","year":"2019","unstructured":"Fukuokaya W, Kimura T, Onuma H et al (2019) Red cell distribution width predicts prostate-specific antigen response and survival of patients with castration-resistant prostate cancer treated with androgen receptor axis-targeted agents. Clin Genitourin Cancer 17:223\u2013230. https:\/\/doi.org\/10.1016\/j.clgc.2019.04.010","journal-title":"Clin Genitourin Cancer"},{"key":"1712_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Halabi S, Luo J et al (2019) prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the prophecy study. J Clin Oncol 37:1120\u20131129. https:\/\/doi.org\/10.1200\/JCO.18.01731","journal-title":"J Clin Oncol"},{"key":"1712_CR8","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/cncr.28890","volume":"120","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Pezaro C, Omlin A et al (2014) Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 120:3346\u20133352. https:\/\/doi.org\/10.1002\/cncr.28890","journal-title":"Cancer"},{"key":"1712_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamaoncol.2018.1621","volume":"4","author":"HI Scher","year":"2018","unstructured":"Scher HI, Graf RP, Schreiber NA et al (2018) Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol 4:1179\u20131186. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1621","journal-title":"JAMA Oncol"},{"key":"1712_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815","journal-title":"N Engl J Med"},{"key":"1712_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, Lu D, Schreiber NA et al (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2:1441\u20131449. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1828","journal-title":"JAMA Oncol"},{"key":"1712_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pros.23443","volume":"78","author":"L-A Tjon-Kon-Fat","year":"2018","unstructured":"Tjon-Kon-Fat L-A, Lundholm M, Schr\u00f6der M et al (2018) Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients. Prostate 78:48\u201353. https:\/\/doi.org\/10.1002\/pros.23443","journal-title":"Prostate"},{"key":"1712_CR13","doi-asserted-by":"publisher","first-page":"68115","DOI":"10.18632\/oncotarget.19242","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Cui M-M, Xu Y et al (2017) Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget 8:68115\u201368122","journal-title":"Oncotarget"},{"key":"1712_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12885-018-5252-2","volume":"19","author":"J Chang","year":"2019","unstructured":"Chang J, Lin G, Ye M et al (2019) Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study. BMC Cancer 19:15. https:\/\/doi.org\/10.1186\/s12885-018-5252-2","journal-title":"BMC Cancer"},{"key":"1712_CR15","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3892\/ol.2014.2495","volume":"8","author":"S Gunduz","year":"2014","unstructured":"Gunduz S, Mutlu H, Uysal M et al (2014) Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer. Oncol Lett 8:2249\u20132252. https:\/\/doi.org\/10.3892\/ol.2014.2495","journal-title":"Oncol Lett"},{"key":"1712_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12957-019-1676-7","volume":"17","author":"W Cao","year":"2019","unstructured":"Cao W, Yao X, Cen D et al (2019) Prognostic role of pretreatment thrombocytosis on survival in patients with cervical cancer: a systematic review and meta-analysis. World J Surg Oncol 17:132. https:\/\/doi.org\/10.1186\/s12957-019-1676-7","journal-title":"World J Surg Oncol"},{"key":"1712_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09537104.2019.1572879","volume":"00","author":"S Rachidi","year":"2019","unstructured":"Rachidi S, Kaur M, Lautenschlaeger T, Li Z (2019) Platelet count correlates with stage and predicts survival in melanoma. Platelets 00:1\u20135. https:\/\/doi.org\/10.1080\/09537104.2019.1572879","journal-title":"Platelets"},{"key":"1712_CR18","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148\u20131159. https:\/\/doi.org\/10.1200\/JCO.2007.12.4487","journal-title":"J Clin Oncol"},{"key":"1712_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1712_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0736-4679(91)90592-4","volume":"9","author":"TC Evans","year":"1991","unstructured":"Evans TC, Jehle D (1991) The red blood cell distribution width. J Emerg Med 9(Suppl 1):71\u201374. https:\/\/doi.org\/10.1016\/0736-4679(91)90592-4","journal-title":"J Emerg Med"},{"key":"1712_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"1712_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195\u2013202. https:\/\/doi.org\/10.1002\/1097-0142(19880101)61:1<195:aid-cncr2820610133>3.0.co;2-y","journal-title":"Cancer"},{"key":"1712_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle M, Stone RL, Menter DG et al (2018) The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 33:965\u2013983. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.002","journal-title":"Cancer Cell"},{"key":"1712_CR24","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1172\/JCI113411","volume":"81","author":"S Karpatkin","year":"1988","unstructured":"Karpatkin S, Pearlstein E, Ambrogio C, Coller BS (1988) Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 81:1012\u20131019. https:\/\/doi.org\/10.1172\/JCI113411","journal-title":"J Clin Invest"},{"key":"1712_CR25","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1161\/ATVBAHA.110.207514","volume":"30","author":"S Jain","year":"2010","unstructured":"Jain S, Harris J, Ware J (2010) Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 30:2362\u20132367. https:\/\/doi.org\/10.1161\/ATVBAHA.110.207514","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1712_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123\u2013134. https:\/\/doi.org\/10.1038\/nrc3004","journal-title":"Nat Rev Cancer"},{"key":"1712_CR27","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1038\/s41598-017-07168-x","volume":"7","author":"Z-Y Yun","year":"2017","unstructured":"Yun Z-Y, Zhang X, Liu Y-S et al (2017) Lower mean platelet volume predicts poor prognosis in renal cell carcinoma. Sci Rep 7:6700. https:\/\/doi.org\/10.1038\/s41598-017-07168-x","journal-title":"Sci Rep"},{"key":"1712_CR28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s10147-017-1158-2","volume":"22","author":"Z-Y Yun","year":"2017","unstructured":"Yun Z-Y, Zhang X, Liu Z-P et al (2017) Association of decreased mean platelet volume with renal cell carcinoma. Int J Clin Oncol 22:1076\u20131080. https:\/\/doi.org\/10.1007\/s10147-017-1158-2","journal-title":"Int J Clin Oncol"},{"key":"1712_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/138161211795049804","volume":"17","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 17:47\u201358. https:\/\/doi.org\/10.2174\/138161211795049804","journal-title":"Curr Pharm Des"},{"key":"1712_CR30","doi-asserted-by":"publisher","first-page":"9213074","DOI":"10.1155\/2019\/9213074","volume":"2019","author":"A Korniluk","year":"2019","unstructured":"Korniluk A, Koper-Lenkiewicz OM, Kami\u0144ska J et al (2019) Mean platelet volume (mpv): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm 2019:9213074. https:\/\/doi.org\/10.1155\/2019\/9213074","journal-title":"Mediators Inflamm"},{"key":"1712_CR31","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.cell.2016.10.042","volume":"167","author":"WJ Astle","year":"2016","unstructured":"Astle WJ, Elding H, Jiang T et al (2016) The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 167:1415\u20131429.e19. https:\/\/doi.org\/10.1016\/j.cell.2016.10.042","journal-title":"Cell"},{"key":"1712_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.abb.2007.01.017","volume":"460","author":"SS Wolf","year":"2007","unstructured":"Wolf SS, Patchev VK, Obendorf M (2007) A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR. Arch Biochem Biophys 460:56\u201366. https:\/\/doi.org\/10.1016\/j.abb.2007.01.017","journal-title":"Arch Biochem Biophys"},{"key":"1712_CR33","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1093\/hmg\/dds361","volume":"21","author":"G Jin","year":"2012","unstructured":"Jin G, Sun J, Kim S-T et al (2012) Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. Hum Mol Genet 21:5222\u20135228. https:\/\/doi.org\/10.1093\/hmg\/dds361","journal-title":"Hum Mol Genet"},{"key":"1712_CR34","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","volume":"31","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Molina A, Li J et al (2013) Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 31:2791\u20132798. https:\/\/doi.org\/10.1200\/JCO.2012.45.4595","journal-title":"J Clin Oncol"},{"key":"1712_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/pcan.2008.36","volume":"12","author":"AJ Armstrong","year":"2009","unstructured":"Armstrong AJ, Halabi S, de Wit R et al (2009) The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 12:88\u201393. https:\/\/doi.org\/10.1038\/pcan.2008.36","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1712_CR36","doi-asserted-by":"publisher","first-page":"180.e19","DOI":"10.1016\/j.urolonc.2018.10.020","volume":"37","author":"M Shiota","year":"2019","unstructured":"Shiota M, Kashiwagi E, Murakami T et al (2019) Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. Urol Oncol 37:180.e19\u2013180.e24. https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.020","journal-title":"Urol Oncol"},{"key":"1712_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.neo.2015.05.003","volume":"17","author":"AB Zaslavsky","year":"2015","unstructured":"Zaslavsky AB, Gloeckner-Kalousek A, Adams M et al (2015) Platelet-synthesized testosterone in men with prostate cancer induces androgen receptor signaling. Neoplasia 17:490\u2013496. https:\/\/doi.org\/10.1016\/j.neo.2015.05.003","journal-title":"Neoplasia"},{"key":"1712_CR38","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA. J Clin Oncol 35:3189\u20133197. https:\/\/doi.org\/10.1200\/JCO.2016.72.1068","journal-title":"J Clin Oncol"},{"key":"1712_CR39","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard A-C, Kim CS et al (2017) Phase III Study comparing a reduced dose of Cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in Postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 35:3198\u20133206. https:\/\/doi.org\/10.1200\/JCO.2016.72.1076","journal-title":"J Clin Oncol"},{"key":"1712_CR40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338\u2013351. https:\/\/doi.org\/10.1056\/NEJMoa1702900","journal-title":"N Engl J Med"},{"key":"1712_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01712-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01712-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01712-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:25:10Z","timestamp":1622589910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01712-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01712-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"22 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained in the form of opt-out on the website. Those who rejected were excluded.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}